×
About 11,928 results

ALLMedicine™ Alanine Aminotransferase Center

Research & Reviews  4,164 results

Validation of cardiogenic shock phenotypes in a mixed cardiac intensive care unit popul...
https://doi.org/10.1002/ccd.30103
Catheterization and Cardiovascular Interventions : Offici... Jentzer JC, Soussi S et. al.

Jan 26th, 2022 - Proposed phenotypes have recently been identified in cardiogenic shock (CS) populations using unsupervised machine learning clustering methods. We sought to validate these phenotypes in a mixed cardiac intensive care unit (CICU) population of pati...

The Association of Alanine Aminotransferase Levels With Myocardial Perfusion Imaging an...
https://doi.org/10.1177/10742484221074585
Journal of Cardiovascular Pharmacology and Therapeutics; Yardeni D, Toledano R et. al.

Jan 26th, 2022 - Studies suggest that non-alcoholic fatty liver disease (NAFLD) is associated with an independent risk of cardiovascular disease (CVD). We utilized a large cohort of patients undergoing myocardial perfusion imaging (MPI) with single photon emission...

Glycerol contained in vaping liquids affects the liver and aspects of energy homeostasi...
https://doi.org/10.14814/phy2.15146
Physiological Reports; Lechasseur A, Mouchiroud M et. al.

Jan 26th, 2022 - Vaping is increasingly popular among the young and adult population. Vaping liquids contained in electronic cigarettes (e-cigarettes) are mainly composed of propylene glycol and glycerol, to which nicotine and flavors are added. Among several biol...

Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatograp...
https://doi.org/10.1093/labmed/lmab118
Laboratory Medicine; Hu C, Zhuang X et. al.

Jan 26th, 2022 - Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) frequently coexist and can act synergistically to drive adverse outcomes of one another. This study aimed to unravel the metabolomic changes in patients with NAFLD and T2...

see more →

Guidelines  2 results

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

Treatment of children with chronic hepatitis B virus infection in the United States: pa...
https://doi.org/10.1002/hep.23934
Hepatology (Baltimore, Md.); Jonas MM, Block JM et. al.

Oct 5th, 2010 - Chronic hepatitis B virus (HBV) infection in children presents a therapeutic challenge for the practitioner. Decisions regarding selection of patients who may benefit from treatment, appropriate timing of treatment, and the choice of antiviral the...

see more →

Drugs  36 results see all →

Clinicaltrials.gov  114 results

South Danish Obesity Initiative, Screening for Unrecognized Obesity Related Disease
https://clinicaltrials.gov/ct2/show/NCT05176132

Jan 20th, 2022 - Obesity is associated with a variety of adverse health problems, and there is currently no effective scalable treatment with a durable effect. Additionally, well-known obesity related health problems are often underdiagnosed. A Danish cohort of pe...

Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT02581215

Jan 12th, 2022 - OUTLINE: This is a multi-center study. EXPERIMENTAL ARM A: Oxaliplatin 85 mg/m^2 over 2-4 hours Irinotecan 165 mg/m^2 over 90 minutes 5-FU 2,400 mg/m^2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia. Ar...

Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy
https://clinicaltrials.gov/ct2/show/NCT01851447

Dec 16th, 2021 - Objectives: the aim of this protocol is to identify biomarker and clinical correlates of changes in the barrier function of skeletal muscle membrane (i.e. cell membrane permeability) before and after routine motor function testing in patients with...

Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
https://clinicaltrials.gov/ct2/show/NCT03600714

Dec 14th, 2021 - Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Based on previous...

Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
https://clinicaltrials.gov/ct2/show/NCT03471624

Dec 2nd, 2021 - Secondary Objective(s): Describe persistence of ALT (alanine aminotransferase) normalization and/or improvement of ALT levels with TAF as with previous anti-HBV treatment To describe trends in serum creatinine and calculated creatinine clearance a...

see more →

News  455 results

Initial Treatment With Lenvatinib Prolongs Survival for Patients With Hepatocellular Carcinoma
https://www.onclive.com/view/initial-treatment-with-lenvatinib-prolongs-survival-for-patients-with-hepatocellular-carcinoma

Jan 21st, 2022 - Cancer (BCLC) stage B2 hepatocellular carcinoma (HCC) helped prolong survival, according to data from a recent multicenter prospective observational study found that was presented at the 2022 Gastrointestinal Cancers Symposium.1 As the standard t...

Sotorasib Approved in Europe for KRAS G12C–Mutated Advanced NSCLC
https://www.onclive.com/view/sotorasib-approved-in-europe-for-kras-g12c-mutated-advanced-nsclc

Jan 10th, 2022 - The European Commission has granted conditional marketing authorization to sotorasib (Lumykras) for the treatment of adult patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor a KRAS G12C mutation and who have progressed f...

FDA Grants Fast Track Designation to Enobosarm for AR+/ER+ Metastatic Breast Cancer
https://www.onclive.com/view/fda-grants-fast-track-designation-to-enobosarm-for-ar-er-metastatic-breast-cancer

Jan 10th, 2022 - The FDA has granted a fast track designation to enobosarm as a potential therapeutic option for patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive, HER2-negative, metastatic breast cancer who progressed on a nonsteroida...

XmAb18087 Shows Encouraging Preliminary Activity in NETs
https://www.onclive.com/view/xmab18087-shows-encouraging-preliminary-activity-in-nets

Jan 3rd, 2022 - Preliminary data from the phase 1 Duet-1 study of XmAb18087 (tidutamab), a humanized, anti–somatostatin receptor 2 (SSTR2), anti–CD3 bispecific antibody, demonstrated a disease control rate (DCR) of 43% across dose levels in patients with neuroend...

EMA Validates Type II Variation Application for Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer
https://www.onclive.com/view/ema-validates-type-ii-variation-application-for-trastuzumab-deruxtecan-in-her2-metastatic-breast-cancer

Jan 3rd, 2022 - The European Medicines Agency (EMA) has validated the Type II Variation application for fam-trastuzumab deruxtecan-nxki (Enhertu) as a treatment for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously rec...

see more →